Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
4:00pm EDT
Change (% chg)

$-0.04 (-5.81%)
Prev Close
$0.74
Open
$0.74
Day's High
$0.74
Day's Low
$0.69
Volume
46,854
Avg. Vol
131,439
52-wk High
$3.35
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million
Friday, 7 Oct 2016 07:00am EDT 

Heat Biologics Inc : Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million year to-date from the exercise of warrants .Says that it has paid down $1.5 million on its commercial loan following recent exercise of warrants.  Full Article

Heat Biologics qtrly loss per share $0.17
Monday, 15 Aug 2016 04:15pm EDT 

Heat Biologics Inc : Heat biologics provides corporate update and reports second quarter 2016 financial results .Qtrly loss per share $0.17.  Full Article

Heat Biologics announces proposed public offering of common stock
Thursday, 21 Jul 2016 04:15pm EDT 

Heat Biologics Inc :Announces proposed public offering of common stock.  Full Article

Heat Biologics presents a poster on its HS-110/Nivolumab
Monday, 6 Jun 2016 07:00am EDT 

Heat Biologics Inc : Additional data illustrates clinical and immune response correlation .Presents A Poster On Its Hs-110/nivolumab combination phase 1b non-small cell lung cancer trial at ASCO annual meeting.  Full Article

Heat Biologics Q1 loss per share $0.50
Wednesday, 11 May 2016 07:00am EDT 

Heat Biologics Inc : Qtrly loss per share $0.50 .Heat Biologics reports first quarter 2016 financial results.  Full Article

Heat Biologics Inc cuts 22 pct of workforce - Reuters News
Thursday, 7 Apr 2016 07:39am EDT 

Heat Biologics Inc:Saving measures and focused corporate strategy to achieve important clinical milestones.Cost-Saving measures include reduction in compensation for remaining leadership team.Cost-Saving measures include a workforce reduction of approximately 22% of company's headcount.Also announced voluntary resignation of two members from its board of directors.Will further decrease operating expenses by advancing only 8 patients enrolled in phase 1b clinical trial evaluating hs-110.Intends to focus resources on near-term milestones for hs-410 and hs-110, both of which are expecting topline data in q4 of 2016.  Full Article

FDA lifts Heat Biologics Inc partial clinical hold
Wednesday, 10 Feb 2016 07:00am EST 

Heat Biologics Inc:FDA lifts Heat Biologics partial clinical hold.Says FDA lifts partial clinical hold on phase 2 trial evaluating hs-410 either alone or in combination with standard of care bcg.Says HEAT will resume patient enrollment on hs-410.Says clinical timelines remain materially unchanged with topline data expected in the fourth quarter of 2016.  Full Article

Heat Biologics reports update on its HS-410 Phase 2 Bladder Cancer Trial
Wednesday, 3 Feb 2016 07:00am EST 

Heat Biologics Inc:Company anticipates clinical timelines for HS-410 to remain materially unchanged.Says the company has recently concluded that the cell line on which HS-410 is based had been previously misidentified.Says FDA has placed hs-410 phase 2 clinical trial on partial clinical hold while they review the updated documentation provided by HEAT.Says believes the partial clinical hold does not relate to concerns regarding the safety of HS-410.Says working with the FDA to resume enrollment in its clinical trial.  Full Article

Heat Biologics Appoints Timothy Creech as Chief Financial Officer
Tuesday, 1 Dec 2015 07:00am EST 

Heat Biologics, Inc:Says appointment of Timothy Creech as Heat's new Chief Financial Officer.  Full Article

Heat Biologics Inc announces clinical trial combining hs-110 and pd-1 checkpoint inhibitor in nsclc
Tuesday, 1 Sep 2015 07:00am EDT 

Heat Biologics Inc:Announces clinical trial combining hs-110 and pd-1 checkpoint inhibitor in nsclc.Says winding down its ongoing phase 2 trial with hs-110, which does not include a checkpoint inhibitor combination.Winding down its ongoing phase 2 trial with hs-110 to instead focus on combinations with checkpoint inhibitors.Says "our expectations around the timing of an hs-110 registration-directed study in nsclc remain unchanged".Expect to release top-line objective response rate, 6-month pfs data on these first 18 patients by the end of 2016.Says checkpoint combination trial to replace existing trial in new treatment landscape.  Full Article

More From Around the Web

BRIEF-Sabby Healthcare Master Fund reports 9.7 pct passive stake in Heat Biologics

* Sabby Healthcare Master Fund Ltd. reports 9.70 percent passive stake in Heat Biologics Inc as on March 28, 2017 - sec filing Source text - http://bit.ly/2nX8nRI Further company coverage: